ABBV·Healthcare·Dividend Aristocrats
Could AbbVie’s latest MAVIRET milestone become another quiet growth lever as investors look beyond its biggest blockbuster franchises? Maik Kemper…
BNTX·Healthcare·Biotech
Can BioNTech Oncology turn its huge cash pile into a real cancer breakthrough before investors lose patience? Maik Kemper Editor…
REGN·Healthcare·Biotech
Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative? Maik…
HIMS·Healthcare
Are Hims & Hers Earnings just a temporary GLP-1 growing pain or the start of a tougher chapter for this…
LLY·Healthcare·Pharma
Are Eli Lilly Earnings riding a temporary GLP‑1 sugar high, or is this the start of a durable new profit…
MRNA·Healthcare·Biotech
Is the Moderna Hantavirus buzz really powering MRNA’s double-digit rally, or are traders simply chasing the next outbreak story? Maik…
CVS·Healthcare
Can the latest CVS Health Earnings beat and upgraded outlook finally turn this battered healthcare giant into a convincing comeback…
MRK.DE·Healthcare
Is the latest ivonescimab setback a temporary stumble or a turning point in the Merck Keytruda Rivalry for lung cancer…
AMGN·Healthcare·Biotech
Are the latest Amgen Earnings a buying opportunity after the stock’s sudden plunge, or a warning sign that growth is…
NVO·Healthcare·Pharma
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom? Maik…